NCT06557265 - NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With Autoimmune Disease (Ntrust-1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

Lupus NephritisGlomerulonephritisPrimary Membranous Nephropathy

Interventions

DRUG

NKX019

NKX019 is an investigational allogeneic CD19-Directed CAR NK

DRUG

Fludarabine, Cyclophosphamide

Lymphodepletion

Trial Locations (13)

10007

RECRUITING

Nkarta Investigational Site, New York

11794

RECRUITING

Nkarta Investigational Site, Stony Brook

30303

RECRUITING

Nkarta Investigational Site, Atlanta

32610

RECRUITING

Nkarta Investigational Site, Gainesville

33133

RECRUITING

Nkarta Investigational Site, Miami

48109

RECRUITING

Nkarta Investigational Site, Ann Arbor

60612

RECRUITING

Nkarta Investigational Site, Chicago

70112

RECRUITING

Nkarta Investigational Site, New Orleans

72201

RECRUITING

Nkarta Investigational Site, Little Rock

75201

RECRUITING

Nkarta Investigational Site, Dallas

77002

RECRUITING

Nkarta Investigational Site, Houston

01608

RECRUITING

Nkarta Investigational Site, Worcester

00674

RECRUITING

Nkarta Investigational Site, Manatí

All Listed Sponsors

lead

Nkarta, Inc.

INDUSTRY